Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Company profile from EODHD, stored Oct 24, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | $284.0K | +278.7% | — | -$126.3M | -$127.1M |
| Mar 2026filed May 5, 2026 | $141.0K | +95.8% | — | -$116.2M | -$104.9M |
| Dec 2025filed Feb 26, 2026 | $132.0K | +83.3% | -142.4% | -$122.7M | -$120.4M |
| Sep 2025filed Nov 5, 2025 | — | — | — | — | — |
| Jun 2025filed Aug 6, 2025 | $75.0K | +4.2% | 100.0% | -$106.8M | -$100.7M |
| Mar 2025filed May 6, 2025 | $72.0K | 0.0% | 100.0% | -$93.9M | -$86.9M |
| Dec 2024filed Mar 3, 2025 | $72.0K | 0.0% | — | -$87.5M | -$79.7M |
| Sep 2024filed Nov 12, 2024 | $86.0K | +19.4% | 100.0% | -$83.5M | -$76.7M |
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 26, 2026 | — | — | — | — | — |
| Dec 2024filed Mar 3, 2025 | $302.0K | -3.8% | — | -$299.0M | -$269.9M |
| Dec 2023filed Feb 27, 2024 | $314.0K | -82.3% | — | -$254.5M | -$237.7M |
| Dec 2022filed Mar 9, 2023 | $1.8M | -40.2% | — | -$134.3M | -$129.9M |
| Dec 2021filed Mar 11, 2022 | $3.0M | +182.2% | — | -$79.7M | -$79.4M |
| Dec 2020filed Mar 26, 2021 | $1.1M | -76.5% | -2,595.6% | -$110.4M | -$110.7M |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched VRDN. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
18,002,311 shares short
+36,643 shares (+0.2%) vs Sep 30, 2026
17.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
17,965,668 shares short
-1,499,583 shares (-7.7%) vs Sep 15, 2026
17.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
19,465,251 shares short
-46,590 shares (-0.2%) vs Aug 31, 2026
18.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
19,511,841 shares short
+485,349 shares (+2.6%) vs Aug 14, 2026
18.9% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
19,026,492 shares short
-208,382 shares (-1.1%) vs Jul 31, 2026
18.5% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
19,234,874 shares short
+311,116 shares (+1.6%) vs Jul 15, 2026
18.7% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind VRDN’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
1 for 15 · reverse split
Effective Nov 13, 2020
Each 15 pre-split shares become 1 post-split share.
Source: EODHD
1 for 15 · reverse split
Effective Nov 7, 2016
Each 15 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if VRDN is in your portfolio and how much it contributes.
Sign inLoading market dates
51 smart-money holders: institutions with a high Holder IQ
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 79 days ago
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 4
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
217 filers reported a long position in VRDN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
51.6%
of the 136M shares 13-F filers reported
Moves vs Q1 2026
10 added0 trimmed
Net shares held
+33%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $305M · 16.6M shares | 16.6M | +8% |
| 2 | BlackRock, Inc. | $157.1M · 8.6M shares | 8.6M | +9.2% |
| 3 | Bellevue Group AG | $123.7M · 6.7M shares | 6.7M | +0.1% |
| 4 | Paradigm Biocapital Advisors LP | $123.5M · 6.7M shares | 6.7M | +113.5% |
| 5 | Kynam Capital Management, LP | $118.6M · 6.5M shares | 6.5M | +175.6% |
| 6 | STATE STREET CORP | $112.5M · 6.1M shares | 6.1M | +31.1% |
| 7 | PRICE T ROWE ASSOCIATES INC /MD/ | $105.6M · 5.7M shares | 5.7M | +79.3% |
| 8 | Fairmount Funds Management LLC | $93.5M · 5.1M shares | 5.1M | +30.1% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $84.1M · 4.6M shares | 4.6M | +9.8% |
| 10 | Deep Track Capital, LP | $66M · 3.6M shares | 3.6M | +157.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inHolders of more than 5% of VRDN file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 20, 2026 | Point72 Asset Management, L.P.13G · passive | 5% |
| Aug 14, 2026 | Kynam Capital Management, LP13G · passive · amended | 5.7% |
| Aug 14, 2026 | Deep Track Capital, LP13G · passive · amended | 3.25%under 5% |
| Aug 14, 2026 | Paradigm Biocapital Advisors LP13G · passive · amended | 6.1% |
| Aug 14, 2026 | PRICE T ROWE ASSOCIATES INC /MD/13G · passive | 5.2% |
| Aug 7, 2026 | STATE STREET CORP13G · passive | 5.5% |
| May 15, 2026 | Bellevue Group AG13G · passive | 6.6% |
| May 13, 2026 | Fairmount Funds Management LLC13D · activist · amended | 14.04% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.